RC108

DRUG4 trials

Sponsors

RemeGen Co., Ltd.

Conditions

Digestive CancerNSCLCNon-Small Cell Lung CancerSolid Tumor

Phase 1

A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors

CompletedNCT04617314

RemeGen Co., Ltd.Solid Tumor

Start: 2021-03-10End: 2025-12-31Updated: 2026-01-06

RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC

RecruitingNCT05821933

RemeGen Co., Ltd.NSCLC

Start: 2023-09-07End: 2026-09-01Target: 106Updated: 2024-04-10

Phase 2

A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor

CompletedNCT05628857

RemeGen Co., Ltd.Digestive Cancer

Start: 2022-11-11End: 2025-12-31Updated: 2026-01-06

A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC

RecruitingNCT06962865

RemeGen Co., Ltd.Non-Small Cell Lung Cancer

Start: 2025-06-30End: 2027-12-31Target: 80Updated: 2025-07-16

Related Papers

RC108 in combination with furmonertinib in patients with locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC) with MET overexpression: Results from a phase Ib/II trial.

Journal of Clinical Oncology2025-05-281 citations